jak2 mutascreen kit  (Ipsogen Inc)

Journal: Cancers

Article Title: Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

doi: 10.3390/cancers14082025

Figure Lengend Snippet: Patients clinical and molecular characteristics.

Article Snippet: JAK2 , TP53 , IDH1/2 status was determined either by individual gene sequencing (quantitative PCR with ipsogen ® Jak2 MutaScreen kit [Qiagen, Hilden, Germany]; Sanger with in-house designed protocol and Droplet Digital PCR [ddPCR] using ddPCRTM IDH1 [R132C/L/S/G/H] and IDH2 [R140L/W/G/Q and R172K] probes [Bio-Rad, Pleasanton, CA, USA] on the QX-200 droplet reader [BioRad] or by Next-Generation sequencing [NGS]).

Techniques: Transplantation Assay

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia

doi: 10.1002/rth2.12315

Figure Lengend Snippet: Characteristics of 48 patients with PV

Article Snippet: Briefly, genomic DNA obtained from peripheral blood mononuclear cells isolated from whole blood was amplified with ipsogen JAK2 MutaScreen RS kit (QIAGEN GmbH, Hilden, Germany) and analyzed by ABI PRISM 7900HT instruments (Applied Biosystems, Austin, TX, USA).

Techniques:

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia

doi: 10.1002/rth2.12315

Figure Lengend Snippet: Univariate analysis of the main parameters in 48 PV patients

Article Snippet: Briefly, genomic DNA obtained from peripheral blood mononuclear cells isolated from whole blood was amplified with ipsogen JAK2 MutaScreen RS kit (QIAGEN GmbH, Hilden, Germany) and analyzed by ABI PRISM 7900HT instruments (Applied Biosystems, Austin, TX, USA).

Techniques:

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia

doi: 10.1002/rth2.12315

Figure Lengend Snippet: Correlations between VWF:Ag and VWF:Act, FVIII, JAK2‐p.V617F, or erythrocytes in 48 patients with PV. (A) Correlation between VWF:Ag and VWF:Act levels. (B) Correlation between VWF:Ag and FVIII levels; (C) Correlation between VWF:Ag and JAK2‐p.V617F allelic burden; (D) Correlation between VWF:Ag and erythrocyte count; the rho and P values are indicated in each panel. FVIII, factor VIII; JAK2‐p.V617F: Janus kinase 2‐p.V617F; PV: polycythemia vera; VWF:Act, von Willebrand factor activity; VWF:Ag, von Willebrand factor antigen

Article Snippet: Briefly, genomic DNA obtained from peripheral blood mononuclear cells isolated from whole blood was amplified with ipsogen JAK2 MutaScreen RS kit (QIAGEN GmbH, Hilden, Germany) and analyzed by ABI PRISM 7900HT instruments (Applied Biosystems, Austin, TX, USA).

Techniques: Activity Assay

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia

doi: 10.1002/rth2.12315

Figure Lengend Snippet: Characteristics of matched patients with PV and ET for VWF comparison

Article Snippet: Briefly, genomic DNA obtained from peripheral blood mononuclear cells isolated from whole blood was amplified with ipsogen JAK2 MutaScreen RS kit (QIAGEN GmbH, Hilden, Germany) and analyzed by ABI PRISM 7900HT instruments (Applied Biosystems, Austin, TX, USA).

Techniques:

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia

doi: 10.1002/rth2.12315

Figure Lengend Snippet: Association between VWF levels and JAK2‐p.V617F mutation in matched patients with PV and ET. Panels A and B show the correlations between VWF antigen and activity, respectively and JAK2‐p.V617F allele burden in 41 patients with PV (red circles); panels C and D show the same correlations in 26 patients with ET (purple triangles) owing the same mutation. ET, essential thrombocythemia; PV, polycythemia vera; VWF, von Willebrand factor

Article Snippet: Briefly, genomic DNA obtained from peripheral blood mononuclear cells isolated from whole blood was amplified with ipsogen JAK2 MutaScreen RS kit (QIAGEN GmbH, Hilden, Germany) and analyzed by ABI PRISM 7900HT instruments (Applied Biosystems, Austin, TX, USA).

Techniques: Mutagenesis, Activity Assay

Journal: Indian Journal of Hematology & Blood Transfusion

Article Title: Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?

doi: 10.1007/s12288-015-0578-2

Figure Lengend Snippet: Table 2

Article Snippet: After obtaining DNA from granulocytes isolated from peripheral-blood samples using conventional gradient centrifugation techniques, a semi-quantitative Ipsogen JAK2 MutaScreen RS kit was used to identify JAK2 V617F/G1849T mutation.

Techniques: